The cancer in question is anaplastic large cell lymphoma, or ALCL, a rare T-cell non-Hodgkin lymphoma that exists in several biologically distinct forms. Systemic ALCL is classified as ALK-positive or ALK-negative depending on whether the tumor carries the ALK fusion oncogene, while separate entities include breast implant-associated ALCL and primary cutaneous ALCL. For most adults with systemic disease, first-line therapy consists of anthracycline-based chemotherapy, with the antibody-drug conjugate brentuximab vedotin combined with cyclophosphamide, doxorubicin and prednisone, known as BV-CHP, now the preferred regimen for CD30-positive cases. When the disease returns or stops responding, options include brentuximab vedotin alone, autologous or allogeneic stem cell transplantation, and ALK inhibitors for relapsed ALK-positive disease. Brentuximab vedotin achieves complete remission in roughly 60 percent of relapsed or refractory patients, but for those who fail to reach remission, median overall survival is only 9.5 months, a statistic that underscores how desperately new strategies are needed.

The patient’s journey began in May 2017, when she presented at age 75 with chronic diarrhea and weight loss. Initial workups for infections, celiac disease and inflammatory bowel disease, along with colonoscopy, all came back negative. Her symptoms worsened, and in July 2017 she developed a small-bowel obstruction requiring surgical resection. Histopathology of the resected tissue delivered the diagnosis: ALK-negative ALCL at stage IVB, meaning the disease had already spread widely. Eight cycles of the standard CHOP chemotherapy regimen produced a complete response, but the lymphoma returned just three months after treatment ended in February 2018. What followed was a years-long cycle of remission and relapse that would exhaust nearly every established option.

Second-line brentuximab vedotin at 1.8 milligrams per kilogram of body weight brought another complete response after eight cycles. Six months after the drug was stopped, the disease relapsed again in February 2019, prompting re-initiation of brentuximab vedotin for an additional 33 cycles. Once more the patient achieved a complete metabolic response, confirmed by PET/CT imaging, and treatment was discontinued in February 2021. Fifteen months later, in May 2022, a third relapse occurred. Because she had developed grade 1 to 2 peripheral neuropathy, a known cumulative toxicity of the antibody-drug conjugate, brentuximab vedotin was withheld. The team instead chose lenalidomide, an immunomodulatory agent given at 15 milligrams daily for 21 days of each 28-day cycle, which stabilized the disease temporarily. After seven cycles, the lymphoma progressed in November 2022.

A final brentuximab vedotin re-challenge, six cycles from April to August 2023, failed entirely. At that point, with few options remaining, the clinicians turned to comprehensive genomic profiling of circulating tumor DNA using the FoundationOne Liquid assay. The September 2023 analysis revealed a tumor mutational burden of 23 mutations per megabase, a figure well above the thresholds generally considered high. Tumor mutational burden and microsatellite instability have emerged as predictive biomarkers for immune checkpoint blockade in several solid tumors, where tumors carrying many mutations produce more abnormal proteins that the immune system can recognize. On that tissue-agnostic rationale, and with no standard alternatives left, the team began nivolumab, initially at 240 milligrams every two weeks and later modified to 480 milligrams every four weeks.

The response was striking. Clinical improvement appeared within two months, and at the first formal response assessment in March 2024, roughly six months after starting therapy, imaging showed a complete metabolic remission. The treatment was not without consequences: in April 2024 the patient developed grade 2 immune-related thyroiditis, an inflammation of the thyroid gland typical of checkpoint inhibitor toxicity, which was managed with thyroid hormone replacement and did not require stopping nivolumab. She continued the drug until November 2025, completing 25 months of treatment. In December 2025 she suffered a myocardial infarction requiring percutaneous coronary intervention with stent implantation, but given her sustained remission, no further nivolumab was administered. At her most recent follow-up in July 2026, eight months after the last dose, she remains in complete metabolic remission with no detectable tumor-associated alterations on repeat liquid biopsy, and reports good overall condition with an ECOG performance status of 1.

To understand how unusual this outcome is, the authors systematically reviewed the literature and found only three previously published adult cases of relapsed or refractory ALCL treated with immune checkpoint inhibitors. Chan and colleagues described a 35-year-old woman with ALK-negative disease who, after multiple chemotherapy failures, autologous transplantation and a relapse three months after allogeneic transplantation, achieved complete response on pembrolizumab within about 70 days, with elevated transaminases as the only side effect. Hebart and colleagues reported a 19-year-old man with ALK-positive disease who had relapsed despite chemotherapy, brentuximab vedotin, the ALK inhibitor crizotinib and autologous transplantation; nivolumab produced complete response within one month, with pneumonitis after 12 cycles treated successfully with corticosteroids. Barta and colleagues included one ALK-negative ALCL patient in a phase 2 trial of PD-1 or PD-L1 inhibition in relapsed T-cell lymphomas; although the trial was halted early for limited efficacy overall, that single patient remained in complete remission for 18 months at publication. A pediatric case reported by Rigaud and colleagues, a 17-year-old with ALK-positive disease treated third-line with nivolumab, adds further support, with rapid response and remission maintained 18 months after initiation.

Taken together, all four adult patients, including the present case, achieved complete remission and remained progression-free across reported observation periods of 4, 9, 18 and 33 months. Where safety data were available, adverse events were manageable and consistent with the established immune-related toxicity profile of PD-1 inhibitors, though the authors caution that patients treated after allogeneic stem cell transplantation face an elevated risk of graft-versus-host disease. The authors are equally clear about the limits of this evidence. Case reports carry strong publication bias, because unsuccessful treatments are far less likely to be published, making it impossible to estimate the true response rate of checkpoint blockade in ALCL. There is currently no validated evidence that tumor mutational burden predicts benefit from immunotherapy in ALCL or other T-cell lymphomas, so the treatment selection in this case was extrapolated from tissue-agnostic approvals in TMB-high solid tumors and should be regarded as hypothesis-generating rather than evidence-based.

Two additional findings may shape future research. Retrospective immunohistochemical analysis of the patient’s original 2017 tumor sample, performed during preparation of the manuscript, showed PD-L1 expression in 95 percent of tumor cells, though whether this contributed to the favorable response remains speculative. The biology of PD-L1 expression also differs between ALCL subtypes: in ALK-positive disease, PD-L1 is driven by oncogenic signaling downstream of ALK with constitutive STAT3 activation playing a central role, whereas ALK-negative disease lacks this driver and PD-L1 may be regulated through alternative STAT3- and MYC-dependent transcriptional programs, a distinction the authors argue demands separate evaluation of the subtypes in future studies. Serial circulating tumor DNA assessment, which tracked this patient’s response and confirmed molecular remission, may also warrant investigation as a monitoring tool in ALCL. The authors conclude that immune checkpoint inhibition should not yet be considered standard treatment for relapsed or refractory ALCL, but may be considered individually, preferably within a clinical trial or structured translational program, for patients who have exhausted established alternatives, and that prospective studies are needed to define efficacy, safety, optimal treatment duration and biomarker-guided patient selection, including rational combinations with brentuximab vedotin whose mechanisms of action may prove complementary.

Subject of Research: Immune checkpoint inhibitor therapy guided by genomic profiling in relapsed or refractory anaplastic large cell lymphoma

Article Title: Immune Checkpoint Inhibitors in Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL): A Case Report and Review of the Literature

Article References: Klenner, C., & Singer, J. (2026). Immune Checkpoint Inhibitors in Relapsed/Refractory Anaplastic Large Cell Lymphoma ( ALCL ): A Case Report and Review of the Literature. Cancer Reports, 9(9), Article e70684. https://doi.org/10.1002/cnr2.70684

Image Credits: AI Generated

DOI: 10.1002/cnr2.70684

Keywords: anaplastic large cell lymphoma, immune checkpoint inhibitors, nivolumab, PD-1 blockade, tumor mutational burden, liquid biopsy, circulating tumor DNA, brentuximab vedotin, PD-L1 expression, T-cell lymphoma, precision oncology, case report

That question took on renewed urgency at the 2024 meeting of the FDA Oncologic Drugs Advisory Committee, which re-examined the comparative efficacy of PD-1 inhibitors plus chemotherapy across PD-L1 expression levels. The committee concluded that patients whose tumors express PD-L1 at a combined positive score or tumor area positivity score of 10 or higher derive the clearest benefit from PD-1 inhibitors, while those scoring below 1 show no meaningful improvement over chemotherapy alone. The large intermediate zone between those thresholds remains contested, and even in higher-expression groups certain populations, notably patients with liver metastases, appear relatively resistant to single-target immunotherapy. Against this backdrop, a new network meta-analysis published in Cancer Reports offers the first systematic indirect comparison of a different immunotherapy architecture: cadonilimab, a tetravalent bispecific antibody that blocks both PD-1 and CTLA-4 within a single molecule.

The research team, registered in the PROSPERO repository and conducted under PRISMA guidelines, searched PubMed, Web of Science, Embase and the Cochrane Library from inception through December 31, 2024, supplementing the database results with conference abstracts from ASCO, ESMO and AACR and with FDA advisory committee documents. Their inclusion criteria were deliberately strict: only Phase III randomized controlled trials in pathologically confirmed, previously untreated, HER2-negative gastric or gastroesophageal junction cancer qualified, and every experimental arm had to combine chemotherapy with either a single-agent anti-PD-(L)1 antibody or the anti-PD-1/CTLA-4 bispecific antibody cadonilimab. From an initial pool of 4,089 publications, screening narrowed the field to eight trials that met all criteria: KEYNOTE-062, ATTRACTION-4, CheckMate-649, KEYNOTE-859, GEMSTONE-303, ORIENT-16, COMPASSION-15 and RATIONALE 305. Together these trials enrolled 7,127 patients, of whom 3,572 received chemotherapy plus an immune checkpoint inhibitor and 3,555 received chemotherapy with placebo.

Because no head-to-head trial has ever compared cadonilimab with a PD-(L)1 antibody, the investigators used a frequentist network meta-analysis, treating all platinum-fluoropyrimidine doublet backbones—XELOX, FOLFOX, SOX and fluorouracil-platinum—as a common chemotherapy comparator node, an approach supported by prior noninferiority trials and systematic reviews showing these regimens are clinically interchangeable. Overall survival, defined as time from randomization to death from any cause, served as the primary endpoint, with progression-free survival and Grade 3 to 5 treatment-related and serious adverse events as secondary measures. Risk of bias was low across the included studies when assessed with the Cochrane RoB 2 tool, and all trials were analyzed on an intention-to-treat basis. Because the network was star-shaped, with cadonilimab connected to the PD-(L)1 inhibitors only through the shared chemotherapy node, formal inconsistency testing was not possible, a structural limitation the authors acknowledge openly.

The headline finding is striking. In the intention-to-treat population, every immunotherapy regimen outperformed chemotherapy alone, but cadonilimab plus chemotherapy delivered the largest survival gain, with a hazard ratio for overall survival of 0.62 (95 percent confidence interval 0.50 to 0.77), compared with hazard ratios of 0.75 to 0.82 for the five PD-(L)1 antibodies: sugemalimab, sintilimab, pembrolizumab, tislelizumab and nivolumab. In the indirect comparison against the pooled PD-(L)1 class, cadonilimab was associated with a statistically significant 22 percent reduction in the hazard of death (hazard ratio 0.78, 95 percent confidence interval 0.62 to 0.98), with essentially no heterogeneity among trials. Treatment ranking by P-score placed cadonilimab first with a probability score of 0.9586, well ahead of the rest of the field, and progression-free survival followed the same pattern, with a hazard ratio of 0.70 (95 percent confidence interval 0.57 to 0.86) favoring the bispecific approach.

The mechanistic rationale for this advantage lies in cadonilimab’s unusual tetravalent design. Gastric adenocarcinomas commonly express the immune checkpoints PD-1 and CTLA-4, which tumors exploit to suppress T-cell responses, and preclinical work has long shown that blocking both pathways synergistically enhances antitumor immunity. Conventional combination immunotherapy with separate PD-1 and CTLA-4 antibodies, tested in the CheckMate 649 trial, was hampered by dose-limiting toxicity and failed to improve survival. Cadonilimab instead packs both binding specificities into one antibody that preferentially accumulates in tumor tissue where PD-1 and CTLA-4 are co-expressed, concentrating dual blockade at the tumor site while sparing normal tissue. That design, the authors argue, explains both the improved efficacy and the tolerability profile observed in COMPASSION-15.

Safety data appear to support that interpretation. Across the included trials, no statistically significant differences emerged between cadonilimab and PD-(L)1 inhibitors in Grade 3 or higher treatment-related adverse events (odds ratio 0.83, 95 percent confidence interval 0.54 to 1.28) or serious adverse events (odds ratio 0.89, 95 percent confidence interval 0.56 to 1.42). Egger’s tests for publication bias were non-significant across all endpoints, and leave-one-out sensitivity analyses left the direction and significance of every primary result unchanged. Still, the authors caution that the confidence intervals around the safety comparisons are wide and rest on a limited number of trials, so a clinically meaningful difference in toxicity cannot be definitively excluded.

The most consequential findings emerge from exploratory subgroup analyses. In patients with low PD-L1 expression—combined positive scores below 10—the hazard ratio for overall survival favored cadonilimab over PD-(L)1 therapy with a point estimate of 0.77 (95 percent confidence interval 0.58 to 1.01), consistent across the CPS below 1 and below 5 cutoffs, while the single-target antibodies showed little or no benefit versus chemotherapy in the same strata. Even more pronounced was the liver metastasis subgroup, where cadonilimab reduced the hazard of death by 33 percent relative to PD-(L)1 inhibitors (hazard ratio 0.67, 95 percent confidence interval 0.49 to 0.93) and halved it relative to chemotherapy alone. This matters because liver metastases deplete peripheral T cells, erode intratumoral T-cell diversity and enrich immunosuppressive regulatory T cells and macrophages, creating a microenvironment that single-agent PD-1 blockade struggles to overcome; the authors propose that simultaneous CTLA-4 inhibition, which suppresses regulatory T cells, counters this biology more effectively. Statistically significant advantages for cadonilimab also appeared in male patients and those with an ECOG performance status of 1, subgroups in which androgen-receptor signaling and heightened systemic inflammation respectively promote T-cell exhaustion that dual checkpoint blockade may more fully reverse.

The authors are careful to frame these subgroup results as hypothesis-generating. All subgroup estimates derive from study-level aggregate data rather than individual patient information, which introduces the risk of ecological bias and limits control of within-trial confounding, and the PD-L1 analyses relied on different immunohistochemistry platforms, albeit assays with demonstrated substantial to excellent concordance in gastric cancer. Ranking analyses are sensitive to network structure and cannot by themselves establish superiority. Nevertheless, the overall picture is internally consistent: for patients whose tumors express high levels of PD-L1, all immunotherapy regimens deliver clear survival benefits over chemotherapy, but for the large populations left in clinical limbo—those with low PD-L1 expression, liver metastases, or intermediate expression where regulatory debate continues—this analysis suggests that a bispecific antibody harnessing two immune escape pathways simultaneously may be the preferable first-line partner for chemotherapy. The findings stop short of Level 1 evidence, and the authors call explicitly for prospective head-to-head trials, but they mark the first quantitative indication that bispecific checkpoint engineering could redraw the treatment algorithm for advanced gastric and gastroesophageal junction cancer.

Subject of Research: Indirect comparison of cadonilimab, a PD-1/CTLA-4 bispecific antibody, versus PD-(L)1 inhibitors as first-line therapy for advanced gastric and gastroesophageal junction cancer

Article Title: Survival Outcomes With Cadonilimab Versus PD‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis

Article References: Yu, Z.-K., Yi, J.-H., Xue, J., Huang, Y.-C., Zhao, Y., Jiang, C., Yin, C.-X., Xia, B., Zhou, Y.-X., He, W.-Z., & Xia, L.-P. (2026). Survival Outcomes With Cadonilimab Versus PD ‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis. Cancer Reports, 9(9), Article e70672. https://doi.org/10.1002/cnr2.70672

Image Credits: AI Generated

DOI: 10.1002/cnr2.70672

Keywords: cadonilimab, gastric cancer, gastroesophageal junction cancer, network meta-analysis, immune checkpoint inhibitors, PD-1, CTLA-4, bispecific antibody, PD-L1 expression, liver metastasis, overall survival, COMPASSION-15